Avantor, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Avantor, Inc. on September 24, 2019, covering events occurring on September 18 and September 20, 2019. The filing addresses significant changes in executive leadership and board composition.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Executive Departure: Bjorn Hofman stepped down as Executive Vice President and Chief Operating Officer on September 18, 2019.
- Leadership Transition: Mr. Hofman's responsibilities are transitioning to Frederic Vanderhaegen (Executive Vice President, Europe) and Tanya Foxe, who joined as Executive Vice President, Operations & Supply Chain on September 30, 2019.
- Board Appointment: Juan Andres was appointed as a Class I director on September 20, 2019, filling a vacant seat. His term expires at the 2020 Annual Meeting of Stockholders.
Outlook, Risks, and Compensation
Mr. Andres brings extensive experience from Moderna, Inc., Novartis AG, and Eli Lilly Company. The Board determined he meets NYSE independence standards. His compensation includes an annual cash retainer of $75,000 (prorated) and a grant of restricted stock units valued at $200,000 (prorated), vesting in full one year from the grant date. No material risks or contingencies were disclosed in this specific filing.
Key Facts for Investor Verification
- Confirm the timeline for the full transition of COO duties to Frederic Vanderhaegen and Tanya Foxe.
- Verify Juan Andres' independence status and any potential conflicts of interest given his role at Moderna, Inc.
- Monitor the impact of the leadership changes on operational stability and supply chain management.